LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Search

Charles River Laboratories International Inc

Geschlossen

BrancheGesundheitswesen

168.66 -1.6

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

167.72

Max

174.52

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.9M

56M

Verkäufe

-27M

1B

KGV

Branchendurchschnitt

592.3

105.69

EPS

2.43

Gewinnspanne

5.529

Angestellte

18,700

EBITDA

-23M

198M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+11.95% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-487M

8.3B

Vorheriger Eröffnungskurs

170.26

Vorheriger Schlusskurs

168.66

Nachrichtenstimmung

By Acuity

21%

79%

49 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Charles River Laboratories International Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Nov. 2025, 21:34 UTC

Ergebnisse

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13. Nov. 2025, 23:45 UTC

Market Talk

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13. Nov. 2025, 23:42 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13. Nov. 2025, 23:41 UTC

Market Talk

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13. Nov. 2025, 23:24 UTC

Ergebnisse

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13. Nov. 2025, 23:24 UTC

Ergebnisse

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13. Nov. 2025, 23:23 UTC

Ergebnisse

JBS NV 3Q EPS 52c >JBS

13. Nov. 2025, 23:23 UTC

Ergebnisse

JBS NV 3Q Sales $22.6B >JBS

13. Nov. 2025, 23:04 UTC

Market Talk

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13. Nov. 2025, 22:02 UTC

Ergebnisse

Nu Holdings 3Q Net $783M >NU

13. Nov. 2025, 22:01 UTC

Ergebnisse

Nu Holdings 3Q Rev $4.2B >NU

13. Nov. 2025, 21:51 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13. Nov. 2025, 21:50 UTC

Ergebnisse

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13. Nov. 2025, 21:45 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13. Nov. 2025, 21:41 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13. Nov. 2025, 21:36 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13. Nov. 2025, 21:36 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13. Nov. 2025, 21:36 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13. Nov. 2025, 21:36 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13. Nov. 2025, 21:36 UTC

Akquisitionen, Fusionen, Übernahmen

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13. Nov. 2025, 21:33 UTC

Market Talk

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13. Nov. 2025, 21:33 UTC

Ergebnisse

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13. Nov. 2025, 21:31 UTC

Ergebnisse

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13. Nov. 2025, 21:25 UTC

Ergebnisse

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13. Nov. 2025, 21:25 UTC

Ergebnisse

Figure Tech Solutions 3Q EPS 34c >FIGR

13. Nov. 2025, 21:23 UTC

Ergebnisse

Intchains Group 3Q Rev $1.3M >ICG

13. Nov. 2025, 21:03 UTC

Ergebnisse

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13. Nov. 2025, 21:02 UTC

Ergebnisse

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13. Nov. 2025, 21:01 UTC

Ergebnisse

Applied Materials 4Q Rev $6.8B >AMAT

13. Nov. 2025, 21:01 UTC

Ergebnisse

Applied Materials 4Q Gross Margin 48.0% >AMAT

Peer-Vergleich

Kursveränderung

Charles River Laboratories International Inc Prognose

Kursziel

By TipRanks

11.95% Vorteil

12-Monats-Prognose

Durchschnitt 192 USD  11.95%

Hoch 225 USD

Tief 165 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Charles River Laboratories International Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

12 ratings

6

Buy

6

Halten

0

Sell

Technischer Score

By Trading Central

117.16 / 144.77Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

49 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat